Patents by Inventor Jürgen Herbert Ernst Kuball
Jürgen Herbert Ernst Kuball has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Patent number: 11686724Abstract: The current invention provides methods to identify ?9?2T-cell receptors (?9?2TCR) that mediate anti-tumour responses. Surprisingly, it was now found that the CDR3 regions of the ?9-T-cell receptor chain and the ?2-T-Cell receptor chain (?2TCR chain) are of importance. Based on these findings, combinatorial-??TCR-chain-exchange (CTE) is proposed as an efficient method for identifying ?9?2TCRs that mediate anti-tumour responses. Using the method of the invention, specific sequences of the respective ?9TCR and ?2TCR chains were identified that mediate anti-tumour responses. Hence, the invention further provides for specific ?9?2TCRs, or fragments thereof, that may be used e.g. in diagnostics or treatment of cancer. The invention further provides for nucleic acid sequences, genetic constructs and retroviral vectors that can be used to express the ?9?2TCRs according to the invention.Type: GrantFiled: July 31, 2020Date of Patent: June 27, 2023Inventors: Jürgen Herbert Ernst Kuball, Victoria Marcu
-
Patent number: 11596654Abstract: Disclosed herein are compositions and methods of treating a subject with cancer. The compositions and methods utilize immunoresponsive cells to effect killing of tumor cells.Type: GrantFiled: December 10, 2018Date of Patent: March 7, 2023Assignee: GADETA B.V.Inventors: Jürgen Herbert Ernst Kuball, Guido Joris Jan Kierkels, Zsolt Sebestyen
-
Publication number: 20220193137Abstract: The current disclosure provides for immune cells expressing immune receptors comprising i) a polypeptide having an antigen binding domain, a TCR ?-chain constant domain, and a TCR ?-chain transmembrane domain; and/or ii) a polypeptide having an antigen binding domain, a TCR ?-chain constant domain, and a TCR ?-chain transmembrane domain. The current disclosure also provides for immune cell expressing immune receptors comprising an antigen binding domain, and a transmembrane domain, wherein the antigen binding domain specifically binds a binding moiety that in turn specifically binds a target, for example, a cancer cell. The immune cells, optionally in combination with the binding moiety, can be used in medical treatment, preferably the treatment of a cancer.Type: ApplicationFiled: April 3, 2020Publication date: June 23, 2022Inventors: Guido Joris Jan Kierkels, Jürgen Herbert Ernst Kuball, Dominik Lock, Andrew Didier Mathew Kaiser
-
Patent number: 11166984Abstract: The present invention relates to a method for identifying ?T-cell (or ?T-cell) receptors chains or parts thereof that mediate an anti-tumor or anti-infection response by identifying amino acid sequences comprising ?T-cells (or ?T-cell) receptors chains or parts thereof that are shared between different donors.Type: GrantFiled: December 10, 2018Date of Patent: November 9, 2021Assignees: UMC UTRECHT HOLDING B.V., Gadeta B.V., Albert-Ludwigs-Universität FreiburgInventors: Jürgen Herbert Ernst Kuball, Anke Janssen, Dennis Beringer, Paul Fisch, Jose Alberto Villacorta Hidalgo
-
Publication number: 20210177901Abstract: The present invention relates to a method for identifying ?T-cell (or ?T-cell) receptors chains or parts thereof that mediate an anti-tumor or anti-infection response by identifying amino acid sequences comprising ?T-cells (or ?T-cell) receptors chains or parts thereof that are shared between different donors.Type: ApplicationFiled: December 17, 2020Publication date: June 17, 2021Applicants: UMC Utrecht Holding B.V., Gadeta B.V., Albert-Ludwigs-Universität FreiburgInventors: Jürgen Herbert Ernst Kuball, Anke Janssen, Dennis Beringer, Paul Fisch, Jose Alberto Villacorta Hidalgo
-
Patent number: 10973895Abstract: The current application provides for exogenous immune receptors that do not require any additional selection marker genes and/or any additional silicide genes. The disclosure allows for the production of engineered T cells that can be enriched for in an untouched manner, i.e., the engineered T cells do not require any interaction with any outside agent and can be selected for by eliminating T cells that express the endogenous alpha beta T cell receptor. Engineered T cells with an exogenous immune receptor are provided that can be differentiated from endogenous T cell receptor and now can be eliminated, i.e., depleted, with a selective antibody that specifically targets the exogenous immune receptor.Type: GrantFiled: November 20, 2015Date of Patent: April 13, 2021Assignee: UMC Utrecht Holding B.V.Inventor: Jürgen Herbert Ernst Kuball
-
Publication number: 20200368278Abstract: Described herein are compositions and methods of treatment for identifying and clearing cell types expressing particular cell surface markers. In one embodiment, the composition comprises a polypeptide construct that selectively binds a J-configuration of CD277 on a target cell, wherein said polypeptide construct is expressed in an engineered cell.Type: ApplicationFiled: May 18, 2018Publication date: November 26, 2020Inventors: Jürgen Herbert Ernst KUBALL, Zsolt SEBESTYEN, Dennis BERINGER, Anna VYBOROVA
-
Publication number: 20200363397Abstract: The current invention provides methods to identify ?9?2T-cell receptors (?9?2TCR) that mediate anti-tumour responses. Surprisingly, it was now found that the CDR3 regions of the ?9-T-cell receptor chain and the ?2-T-Cell receptor chain (?2TCR chain) are of importance. Based on these findings, combinatorial-??TCR-chain-exchange (CTE) is proposed as an efficient method for identifying ?9?2TCRs that mediate anti-tumour responses. Using the method of the invention, specific sequences of the respective ?9TCR and ?2TCR chains were identified that mediate anti-tumour responses. Hence, the invention further provides for specific ?9?2TCRs, or fragments thereof, that may be used e.g. in diagnostics or treatment of cancer. The invention further provides for nucleic acid sequences, genetic constructs and retroviral vectors that can be used to express the ?9?2TCRs according to the invention.Type: ApplicationFiled: July 31, 2020Publication date: November 19, 2020Inventors: Jürgen Herbert Ernst KUBALL, Elsa-Cordula GRÜNDER
-
Patent number: 10578609Abstract: The current invention provides methods to identify ?9?2T-cell receptors (?9?2TCR) that mediate anti-tumour responses. Surprisingly, it was now found that the CDR3 regions of the ?9-T-cell receptor chain and the ?2-T-Cell receptor chain (?2TCR chain) are of importance. Based on these findings, combinatorial-??TCR-chain-exchange (CTE) is proposed as an efficient method for identifying ?9?2TCRs that mediate anti-tumour responses. Using the method of the invention, specific sequences of the respective ?9TCR and ?2TCR chains were identified that mediate anti-tumour responses. Hence, the invention further provides for specific ?9?2TCRs, or fragments thereof, that may be used e.g. in diagnostics or treatment of cancer. The invention further provides for nucleic acid sequences, genetic constructs and retroviral vectors that can be used to express the ?9?2TCRs according to the invention.Type: GrantFiled: December 9, 2016Date of Patent: March 3, 2020Assignee: Gadeta B.V.Inventors: Jürgen Herbert Ernst Kuball, Elsa-Cordula Gründer
-
Publication number: 20190271688Abstract: The current invention provides methods to identify ?9?2T-cell receptors (?9?2TCR) that mediate anti-tumour responses. Surprisingly, it was now found that the CDR3 regions of the ?9-T-cell receptor chain and the ?2-T-Cell receptor chain (?2TCR chain) are of importance. Based on these findings, combinatorial-??TCR-chain-exchange (CTE) is proposed as an efficient method for identifying ?9?2TCRs that mediate anti-tumour responses. Using the method of the invention, specific sequences of the respective ?9TCR and ?2TCR chains were identified that mediate anti-tumour responses. Hence, the invention further provides for specific ?9?2TCRs, or fragments thereof, that may be used e.g. in diagnostics or treatment of cancer. The invention further provides for nucleic acid sequences, genetic constructs and retroviral vectors that can be used to express the ?9?2TCRs according to the invention.Type: ApplicationFiled: February 13, 2019Publication date: September 5, 2019Inventors: Jürgen Herbert Ernst Kuball, Elsa-Cordula Gründer
-
Publication number: 20190209613Abstract: The present invention relates to a method for identifying ?T-cell (or ?T-cell) receptors chains or parts thereof that mediate an anti-tumor or anti-infection response by identifying amino acid sequences comprising ?T-cells (or ?T-cell) receptors chains or parts thereof that are shared between different donors.Type: ApplicationFiled: December 10, 2018Publication date: July 11, 2019Inventors: Jürgen Herbert Ernst Kuball, Anke Janssen, Dennis Beringer, Paul Fisch, Jose Alberto Villacorta Hidalgo
-
Patent number: 10324083Abstract: The current invention provides methods to identify ?9?2T-cell receptors (?9?2TCR) that mediate anti-tumor responses. Surprisingly, it was now found that the CDR3 regions of the ?9-T-cell receptor chain and the ?2-T-Cell receptor chain (?2TCR chain) are of importance. Based on these findings, combinatorial-??TCR-chain-exchange (CTE) is proposed as an efficient method for identifying ?9?2TCRs that mediate anti-tumor responses. Using the method of the invention, specific sequences of the respective ?9TCR and ?2TCR chains were identified that mediate anti-tumor responses. Hence, the invention further provides for specific ?9?2TCRs, or fragments thereof, that may be used e.g. in diagnostics or treatment of cancer. The invention further provides for nucleic acid sequences, genetic constructs and retroviral vectors that can be used to express the ?9?2TCRs according to the invention.Type: GrantFiled: December 14, 2017Date of Patent: June 18, 2019Assignee: Gadeta B.V.Inventors: Jürgen Herbert Ernst Kuball, Elsa-Cordula Gründer
-
Publication number: 20190169260Abstract: Disclosed herein are compositions and methods of treating a subject with cancer. The compositions and methods utilize immunoresponsive cells to effect killing of tumor cells.Type: ApplicationFiled: December 10, 2018Publication date: June 6, 2019Inventors: Jürgen Herbert Ernst Kuball, Guido Joris Jan Kierkels, Zsolt Sebestyen
-
Publication number: 20180188234Abstract: The current invention provides methods to identify ?9?2T-cell receptors (?9?2TCR) that mediate anti-tumour responses. Surprisingly, it was now found that the CDR3 regions of the ?9-T-cell receptor chain and the ?2-T-Cell receptor chain (?2TCR chain) are of importance. Based on these findings, combinatorial-??TCR-chain-exchange (CTE) is proposed as an efficient method for identifying ?9?2TCRs that mediate anti-tumour responses. Using the method of the invention, specific sequences of the respective ?9TCR and ?2TCR chains were identified that mediate anti-tumour responses. Hence, the invention further provides for specific ?9?2TCRs, or fragments thereof, that may be used e.g. in diagnostics or treatment of cancer. The invention further provides for nucleic acid sequences, genetic constructs and retroviral vectors that can be used to express the ?9?2TCRs according to the invention.Type: ApplicationFiled: December 14, 2017Publication date: July 5, 2018Inventors: Jürgen Herbert Ernst Kuball, Elsa-Cordula Gründer
-
Patent number: 9891211Abstract: The current invention provides methods to identify ?9?2T-cell receptors (?9?2TCR) that mediate anti-tumor responses. Surprisingly, it was now found that the CDR3 regions of the ?9-T-cell receptor chain and the ?2-T-Cell receptor chain (?2TCR chain) are of importance. Based on these findings, combinatorial-??TCR-chain-exchange (CTE) is proposed as an efficient method for identifying ?9?2TCRs that mediate anti-tumor responses. Using the method of the invention, specific sequences of the respective ?9TCR and ?2TCR chains were identified that mediate anti-tumor responses. Hence, the invention further provides for specific ?9?2TCRs, or fragments thereof, that may be used e.g. in diagnostics or treatment of cancer. The invention further provides for nucleic acid sequences, genetic constructs and retroviral vectors that can be used to express the ?9?2TCRs according to the invention.Type: GrantFiled: March 28, 2013Date of Patent: February 13, 2018Assignee: Gadeta B.V.Inventors: Jürgen Herbert Ernst Kuball, Elsa-Cordula Gründer
-
Publication number: 20170319674Abstract: The current application provides for exogenous immune receptors that do not require any additional selection marker genes and/or any additional silicide genes. The disclosure allows for the production of engineered T cells that can be enriched for in an untouched manner, i.e., the engineered T cells do not require any interaction with any outside agent and can be selected for by eliminating T cells that express the endogenous alpha beta T cell receptor. Engineered T cells with an exogenous immune receptor are provided that can be differentiated from endogenous T cell receptor and now can be eliminated, i.e. depleted, with a selective antibody that specifically targets the exogenous immune receptor.Type: ApplicationFiled: November 20, 2015Publication date: November 9, 2017Applicants: UMC Utrecht Holding B.V., UMC Utrecht Holding B.V.Inventor: Jürgen Herbert Ernst Kuball
-
Publication number: 20170174741Abstract: The current invention provides methods to identify ?9?2T-cell receptors (?9?2TCR) that mediate anti-tumour responses. Surprisingly, it was now found that the CDR3 regions of the ?9-T-cell receptor chain and the ?2-T-Cell receptor chain MICR chain) are of importance. Based on these findings, combinatorial-??TCR-chain-exchange (CTE) is proposed as an efficient method for identifying ?9?2TCRs that mediate anti-tumour responses. Using the method of the invention, specific sequences of the respective ?9TCR and ?2TCR chains were identified that mediate anti-tumour responses. Hence, the invention further provides for specific ?9?2TCRs, or fragments thereof, that may be used e.g. in diagnostics or treatment of cancer. The invention further provides for nucleic acid sequences, genetic constructs and retroviral vectors that can be used to express the ?9?2TCRs according to the invention.Type: ApplicationFiled: December 9, 2016Publication date: June 22, 2017Inventors: Jürgen Herbert Ernst Kuball, Elsa-Cordula Gründer
-
Patent number: 9546998Abstract: The current invention provides methods to identify ?9?2T-cell receptors (?9?2TCR) that mediate anti-tumor responses. Surprisingly, it was now found that the CDR3 regions of the ?9-T-cell receptor chain and the ?2-T-Cell receptor chain (?2TCR chain) are of importance. Based on these findings, combinatorial-??TCR-chain-exchange (CTE) is proposed as an efficient method for identifying ?9?2TCRs that mediate anti-tumor responses. Using the method of the invention, specific sequences of the respective ?9TCR and ?2TCR chains were identified that mediate anti-tumor responses. Hence, the invention further provides for specific ?9?2TCRs, or fragments thereof, that may be used e.g. in diagnostics or treatment of cancer. The invention further provides for nucleic acid sequences, genetic constructs and retroviral vectors that can be used to express the ?9?2TCRs according to the invention.Type: GrantFiled: March 28, 2013Date of Patent: January 17, 2017Assignee: Gadeta B.V.Inventors: Jürgen Herbert Ernst Kuball, Elsa-Cordula Gründer
-
Patent number: 9518978Abstract: The current invention provides methods to identify ?9?2T-cell receptors (?9?2TCR) that mediate anti-tumor responses. Surprisingly, it was now found that the CDR3 regions of the ?9-T-cell receptor chain and the ?2-T-Cell receptor chain (?2TCR chain) are of importance. Based on these findings, combinatorial-??TCR-chain-exchange (CTE) is proposed as an efficient method for identifying ?9?2TCRs that mediate anti-tumor responses. Using the method of the invention, specific sequences of the respective ?9TCR and ?2TCR chains were identified that mediate anti-tumor responses. Hence, the invention further provides for specific ?9?2TCRs, or fragments thereof, that may be used e.g. in diagnostics or treatment of cancer. The invention further provides for nucleic acid sequences, genetic constructs and retroviral vectors that can be used to express the ?9?2TCRs according to the invention.Type: GrantFiled: March 28, 2013Date of Patent: December 13, 2016Assignee: Gadeta B.V.Inventors: Jürgen Herbert Ernst Kuball, Elsa-Cordula Gründer
-
Publication number: 20150050670Abstract: The current invention provides methods to identify ?9?2T-cell receptors (?9?2TCR) that mediate anti-tumour responses. Surprisingly, it was now found that the CDR3 regions of the ?9-T-cell receptor chain and the ?2-T-Cell receptor chain (?2TCR chain) are of importance. Based on these findings, combinatorial-??TCR-chain-exchange (CTE) is proposed as an efficient method for identifying ?9?2TCRs that mediate anti-tumour responses. Using the method of the invention, specific sequences of the respective ?9TCR and ?2TCR chains were identified that mediate anti-tumour responses. Hence, the invention further provides for specific ?9?2TCRs, or fragments thereof, that may be used e.g. in diagnostics or treatment of cancer. The invention further provides for nucleic acid sequences, genetic constructs and retroviral vectors that can be used to express the ?9?2TCRs according to the invention.Type: ApplicationFiled: March 28, 2013Publication date: February 19, 2015Inventors: Jürgen Herbert Ernst Kuball, Elsa-Cordula Gründer